Inactivating monoclonal antibodies against SOST, a inhibitor of the negative regulation of WNT/β-catenin signaling, has been shown to be a candidate for the prevention and treatment of osteoporosis (Rossini, Gatti & Adami, 2013). This evidence concerns the gene SOST and osteoporosis.